Anai S, et al. - Researchers assessed how polymorphisms of uridine diphosphate (UDP)–glucuronosyltransferase 1A1 (UGT1A1, largely responsible for the glucuronidation of etoposide) are related to toxicity profile during platinum-etoposide doublet therapy in small cell lung cancer (SCLC) patients. They determined the occurrence of adverse events during treatment in SCLC patients who had platinum-etoposide doublet therapy and molecular testing for UGT1A1 genotype. These patients were reviewed. Findings demonstrated that, UGT1A1 polymorphisms were associated with toxicity of platinum-etoposide doublet therapy in SCLC patients. Based on the findings, patients carrying such variant alleles and receiving this treatment deserve close monitoring for toxicity, especially nephrotoxicity.